Remote Informed Consent

Methods other than an “in person” consent discussion may be acceptable if those methods allow for an adequate exchange of information, a method to ensure that the signee of the consent form is the person who plans to enroll as a subject or is the legally authorized representative (LAR) of the subject, and, unless waived, documentation of consent where the subject or LAR signs and dates the document.

No single set of recommendations fit all research needs. Options vary with the risk level and applicable regulations. Also, consider what would be feasible or preferable for your subject population. You may want to propose multiple or contingency plans to meet situational or individual participant needs.

Your remote consent process must be prospectively reviewed and approved by the Institutional Review Board (IRB). Describe your plan(s) in the Research Description section (Informed Consent Process sub-section) of the E-IRB application. Your consent plan should include how the consent form is presented/reviewed, signatures obtained, copies provided to subjects, and, if applicable, screenshots showing the final formatting and features the subjects would see. Include your consent document(s) as an attachment to your IRB application. Questions? Call ORI; staff are here to help.

MINIMAL RISK RESEARCH

■ Intent is to receive a signed and dated paper document.
  ○ Mail, fax, or email the consent form, and HIPAA Authorization, if applicable, to the potential subject and/or legally authorized representative (LAR) in advance of the remote process – if using an LAR, you must have IRB approval in advance.
  ○ Once the potential subject has the form and you have verified correct individuals are connected by phone or video, talk through the consent, answer questions, ensure the subject understands and consent is voluntary. Document the conversation by noting the date, names of individuals present, how the process was conducted, discussion points, and how the signed document is to be returned.
  ○ The subject returns the signed document via a prepaid envelope OR returns the signed document by scanning or photographing the signed and dated form and then sending the scan/photograph to the investigator by email/fax/upload, etc.
  ○ Once the investigator receives the signed/dated consent form, the person who conducted the consent conference prints his/her/their name and enters the current date on the form.
  ○ Do not initiate study procedures until the subject’s signed consent document is received.
  ○ Ensure the subject is provided with a copy of the form(s) he/she/they signed.
  ○ If added security is needed or if HIPAA applies to the research, consider the following:
    ▪ Cybersecurity precautions: Information Technology Services (ITS) and HealthCare IT have enabled Data Loss Prevention (DLP) in Microsoft Office 365 which is a feature that will auto-encrypt certain email messages based on the information contained within them. You can trigger the feature by using keywords “#secure” or “#encrypt” in the subject line. The recipient then receives instructions on how to open the message. See more information at https://www.uky.edu/its/news/its-notification-dlp-email-encryption or contact ITS Customer Services at 859-218-HELP (4357) or 218help@uky.edu.
    ▪ Standard UK Zoom also offers security options and encryption. View Security under Settings for additional security steps such as setting passcodes or requiring participants to authenticate prior to joining.
    ▪ See Question 10 on the FAQ’s on Telehealth during COVID-19 for other “non-public facing” platforms that allow only the intended parties to participate in the videoconferencing. Unacceptable public-facing products are also listed.
    ▪ UK Healthcare has a HIPAA compliant contract with Zoom for secure videoconferencing. Go to ukth.zoom.us to set up an account with your linkblue ID and password.
• **Research Conducted with a Waiver of Documentation of Informed Consent (not applicable for FDA-regulated research)**
  - Requires a consent form (e.g., cover letter, verbal script) and process, but the investigator does not have to collect a signed document.
  - If consent is not built into the data collection instrument, mail, fax, or email the consent form to the subject in advance.
  - Once the potential subject has the form and you have verified correct individuals are connected by phone or video, talk through the consent, answer questions, ensure the subject understands and consent is voluntary. You may document the conversation by noting the date, names of individuals present, how the process was conducted, discussion points, and whether the person agreed to enroll.
  - Employ cybersecurity precautions or secure/HIPAA videoconferencing as applicable.

• **Electronic Informed Consent** – E-consent refers to the use of electronic systems and processes that may employ multiple electronic media, including text, graphics, audio, video, podcasts, passive and interactive websites, biological recognition devices, and card readers, to convey information related to the study and to obtain and document informed consent. (For FDA-Regulated research, see Electronic Informed Consent for FDA Regulated Research).
  - To have a valid signature, your e-consent process should have:
    - the ability to prove that the actual signer is the intended signer;
    - the inability of the signer to deny the signature; and
    - an assurance that neither the record nor the signature have been altered since the moment of signing. To achieve this, the electronic signature and date should be linked to the document so that it cannot be modified or tampered with.
  - Having the individual type their name on a word document or other format that allows the signature to be tampered with is not valid. If you choose an invalidated signature method for minimal risk research that involves no procedures for which written consent is normally required, request an IRB waiver of documentation.
  - If using PDF to collect signature, set your verification preferences in advance. This helps ensure that Digital Signatures are valid when you open a PDF and verification details appear with the signature. See Adobe Validating Digital Signatures.
  - Ensure the subject is provided with a copy of the form(s) he/she/they signed.
  - E-consent may be formatted to include the printed name of the person obtaining consent, or the study personnel may print their name on the document when received.
  - Example software offered by UK is REDCap, which is a HIPAA compliant electronic system that can be used to create your e-consent, verify identity, and collect signatures for research with automatic email of copies sent to both the subject and the investigator.
    - Use the REDCap e-consent template to enable the subject to verify consent and electronically sign and date the document (i.e., not just clicking YES to enroll).
    - REDCap is housed and maintained by CCTS (For additional information, view the REDCap consent feature webinar or CCTS Biobank video demo).

**GREATER THAN MINIMAL RISK / NOT FDA-REGULATED**

• Intent is to receive a **signed and dated paper document** from the subject – the consent process may be conducted as described in the minimal risk category above.

• **Electronic Informed Consent** – the consent process may be conducted as described in the minimal risk category above.
GREATER THAN MINIMAL RISK/FDA-REGULATED

- Intent is to receive a signed and dated paper document from the subject – the consent process may be conducted as described in the minimal risk category above.

- Electronic Informed Consent for FDA-Regulated Research – E-consent refers to the use of electronic systems and processes that may employ multiple electronic media, including text, graphics, audio, video, podcasts, passive and interactive websites, biological recognition devices, and card readers, to convey information related to the study and to obtain and document informed consent.
  - For FDA-regulated research, software systems must be compliant with all requirements under FDA Part 11 regulation (e.g., restricted access, administrative controls, training, identity verification, etc.).
    - FDA does not certify systems for Part 11 compliance.
    - Sponsor’s may provide Part 11 compliant electronic consent. For investigator-initiated research, refer to the Resource section below for Part 11 options including DocuSign Part 11, Adobe Sign Part 11, and COVID MyStudies App which FDA has made available at no cost as resources allow.
    - Generally, there is no “out of the box” software solution as the customer is responsible for setting features, demonstrating compliance, providing/documenting training, and administering operational policies and procedures. This means your unit, department, college has the responsibility to be able to demonstrate that the software is fit for its intended use and the system meets the applicable regulations should your protocol be audited. You may request a statement from the sponsor or vendor of the electronic system used for obtaining the electronic signature that the system meets the relevant requirements contained in Part 11 and maintain documentation that your site has fulfilled applicable customer requirements such as training, password controls, etc.
  - To capture consent on this type of system, you can use:
    - Electronic signature - a computer data compilation of any symbol(s) executed, adopted, or authorized by an individual to be a legally binding equivalent of the individual’s handwritten signature. Methods include computer readable ID cards, biometrics, digital (cryptographic) signatures, and user/password combinations. Electronic signatures must comply with 21 CFR 11.5 & 11.7 signature requirements:
      - The printed name of the signer;
      - Date and time when the signature was executed;
      - Meaning (i.e., consent); and
      - Linked to their respective electronic records to ensure that it cannot be excised, copied, or otherwise transferred (i.e., tampered with).
    - Handwritten signatures executed to electronic records - hand scripted signatures executed to electronic records by signing with a stylus, finger, or cursor drawing. These may be used in a hybrid process where the only electronic component is the documentation (signature) of informed consent. Handwritten signatures executed to electronic records must comply with 21 CFR 11.7:
      - Linked to their respective electronic records to ensure that it cannot be excised, copied, or otherwise transferred (i.e., tampered with).
  - Also see ORI Outline of FDA Guidance for Industry: Use of Electronic Informed Consent in Clinical Investigations.
SUBJECT IN MEDICAL ISOLATION

The FDA Covid-19 Guidance provides the following process which may be used when Electronic Informed Consent is not available or feasible:

- A consent form, and HIPAA Authorization, if applicable, is provided to the patient (or, if applicable, the LAR) by a health care worker who can enter the room.
- If direct communication with the patient in isolation is not feasible or safe, the investigator obtains the patient’s phone number and arranges a three-way call or video conference with the patient, an impartial witness, and, if feasible, additional people as requested by the patient.
- If the signed and dated paper consent document can safely be collected, the person who conducted the consent conference prints his/her/their name and enters the current date on the form and provides the subject with a copy of the form(s) he/she/they signed.
- If the signed informed consent document cannot be safely collected from the patient’s location and included in the study records, the FDA considers the following two options acceptable for providing documentation that the patient signed the informed consent document:
  - Method 1:
    - Photograph of the signed and dated document is transmitted to the investigator or research staff.
    - Place the photo of the signed consent in the subject’s study record along with an attestation that states how the photograph was obtained and that it is a photograph of the informed consent document signed by the patient.
  - OR -
  - Method 2:
    - Three-way communication with a witness who is not otherwise connected with the research and, if desired and feasible, additional individuals requested by the patient.
    - Alternatively, in lieu of using a witness, a recording of the conversation can be made and retained in the study record.
    - After reviewing the consent and answering all questions, obtain verbal confirmation from the patient that they would like to participate, and they have signed and dated the consent document in their possession. Document the following in the study records:
      1. a signed and dated attestation by the witness who participated on the call, that the patient confirmed their agreement to participate and signed and dated the informed consent document (or call recording); and
      2. a signed and dated attestation by the investigator/designee stating why the informed consent document signed by the patient was not retained (e.g., contaminated).

RESOURCES

UK Telehealth
UK HIPAA compliant Zoom ukth.zoom.us
FAQs on Telehealth and HIPAA during the COVID-19 nationwide public health emergency
FDA Guidance on Conduct of Clinical Trials During COVID-19 Public Health Emergency
Office for Human Research Protections (OHRP) Guidance on Covid-19
UK CCTS Clinical Research Update October 2020 session on Remote Informed Consent
UK CCTS Webinar on REDCap Mobile App and Informed Consent feature
ORI Use of Electronic Informed Consent in Clinical Investigations Summary of Federal Guidance
CCTS biobank consent video demo on REDCap consent for isolation patients
ORI COVID-19 FAQ, “What e-consent options are FDA Part 11 compliant for FDA-regulated clinical trials?”

Perficient Ultimate Guide to FDA CFR Part 11

TrialHub Article listing commercial vendors which may offer discount during COVID-19 pandemic

DocuSign Part 11 Module

Adobe Sign 21 CFR Part 11 manual

Verifying Adobe Signatures

FDA COVID MyStudies App